Prostate-specific antigen (PSA) screening has contributed to the decrease in PCa mortality, but also poses the risk of overdiagnosis (since it can be increased also in benign prostatic hyperplasia, prostatitis and other non-malignant conditions) and consequent complications from unnecessary treatment [10,11]. This evidence concerns the gene KLK3 and urogenital neoplasm.